Skip to main content
OpenTrials

Clinical trial condition

Recurrent Renal Cell Carcinoma

Explore clinical trials studying Recurrent Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Renal Cell Carcinoma trial results

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +18 more
Locations
  • University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • The University of Arizona Medical Center-University Campus Tucson, Arizona, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 214 locations
View Trial Details
Completed

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

NCT00378703

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • The University of Arizona Medical Center-University Campus Tucson, Arizona, United States
View all 559 locations
View Trial Details
Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +18 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View all 30 locations
View Trial Details
Completed

Vorinostat in Treating Patients With Kidney Cancer

NCT00278395

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Cancer Therapy and Research Center at The UT Health Science Center at San Antonio San Antonio, Texas, United States
  • Institute for Drug Development San Antonio, Texas, United States
View Trial Details
Completed

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +47 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
View Trial Details
Completed

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

NCT01141569

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • London Regional Cancer Program London, Ontario, Canada
  • Ottawa Health Research Institute-General Division Ottawa, Ontario, Canada
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Completed

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00227760

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
  • London Regional Cancer Program London, Ontario, Canada
View Trial Details

Related conditions